On May 12, 2026, Imunon, Inc. (IMNN) announced financial results for the first quarter of 2026 and provided a business update. The company announced that the Phase 3 OVATION 3 trial is expected to have approximately 80 patients enrolled by the first quarter of 2027 and be fully enrolled by the first quarter of 2029. We anticipate multiple scientific presentations this year at medical conferences highlighting additional data from the Phase 2 OVATION 2 trial, including translational data and the final overall survival data. While noting the difficulties in the capital funding environment, the company is currently opting for a bridge financing strategy but is open to more "creative" structures intended to minimize dilution, including deals utilizing preferred shares. We anticipate at least one additional financing in the second half of the year.